Cancer research is advancing into a new era, defined by precision, complexity, and the convergence of multiple therapeutic modalities. Traditional approaches are rapidly being augmented, and in many cases outpaced, by breakthroughs in immunotherapy, targeted agents, cell and gene engineering, and next-generation delivery platforms. Coupled with increasingly sophisticated diagnostic technologies, these innovations are not just expanding the therapeutic landscape, they are fundamentally redefining how cancer is understood, studied, and treated.

As the field evolves, there is a clear shift toward integrated, translational strategies that bridge early discovery with clinical impact. Reflecting this momentum, we recently partnered with The Scientist to host a symposium convening leading experts across oncology and immuno-oncology. The program explored cutting-edge advances spanning preclinical research through translational development, highlighting how next-generation therapeutic approaches are shaping the future of cancer care.

If you were unable to attend the live event, recordings of all featured presentations are available below.

1. Strategies in Addressing Therapy Resistance in Solid Tumors
2. Human Co-Culture Models In Pre-Clinical Research: Applications in Immunology, Infectious Disease and Oncology
3. The Rising Tide of GI Cancers in Younger Adults: Why We Urgently Need New Therapies
4. Next-Generation Oncology Drug Discovery: Leveraging RASTRUM™ 3D Models to Accelerate Emerging Cancer Therapies
5. Who Actually Needs Treatment? Precision Diagnostics, Metastatic Risk, and the Future of Cancer Care
6. The Dark Proteome in Pancreatic Cancer: A Rich Source of Cancer-Restricted Cryptic Antigens
7. Cellular Networks that Lead to Intra-Tumoral Heterogenicity Associated Resistance in Metastatic TNBCs
8. Modulating the Immune System through Synthetic Induced Mesenchymal Stem Cell (iMSC) Therapies
9. Extrachromosomal DNA (ecDNA): Cancer’s Dynamic Circular Genome

Strategies in Addressing Therapy Resistance in Solid Tumors

Neil Bhowmick, PhD

President and Chief Scientific Officer, Kairos Pharma  

Human Co-Culture Models In Pre-Clinical Research: Applications in Immunology, Infectious Disease and Oncology

Ethan Shelkey, PhD

Principal Scientist, R&D, Lonza  

The Rising Tide of GI Cancers in Younger Adults: Why We Urgently Need New Therapies

Thejus Jayakrishnan, MD

Associate Oncologist, Dana-Farber Cancer Institute  

Next-Generation Oncology Drug Discovery: Leveraging RASTRUM™ 3D Models to Accelerate Emerging Cancer Therapies

Sean Porazinski, PhD

Head of Scientific Programs, Inventia Life Science  

Who Actually Needs Treatment? Precision Diagnostics, Metastatic Risk, and the Future of Cancer Care

Harvey Homan, PhD

Chief Executive Officer and Cofounder, MetasTx  

The Dark Proteome in Pancreatic Cancer: A Rich Source of Cancer-Restricted Cryptic Antigens

William Freed-Pastor, MD, PhD

Medical Oncologist and Physician-Scientist, Dana-Farber Cancer Institute; Assistant Professor, Harvard Medical School  

Cellular Networks that Lead to Intra-Tumoral Heterogenicity Associated Resistance in Metastatic TNBCs

Diego Pedroza, PhD

Instructor, Baylor College of Medicine  

Modulating the Immune System through Synthetic Induced Mesenchymal Stem Cell (iMSC) Therapies

Sanjeev Luther, PhD

Chief Executive Officer, Ernexa Therapeutics

Robert Pierce, MD

Chief Scientific Officer, Ernexa Therapeutics  

Extrachromosomal DNA (ecDNA): Cancer’s Dynamic Circular Genome

Paul Mischel, MD

Professor and Vice Chair for Research, Department of Pathology, Stanford University